• On 27 June 2026, Baxter International Inc. (NYSE:BAX) was added to both the Russell 2500 Index and the Russell 2500 Value Benchmark, expanding its presence in widely followed US equity benchmarks.
• This dual index inclusion can meaningfully affect how institutional investors and index-tracking funds gain exposure to Baxter, potentially reshaping its investor base and trading profile.
• Next, we’ll examine how Baxter’s inclusion in the Russell 2500 Value Index could influence its existing investment narrative and risk-reward profile.

Find 45 companies with promising cash flow potential yet trading below their fair value.

Baxter International Investment Narrative Recap

To own Baxter today, you need to believe its hospital-focused portfolio and ongoing restructuring can translate into a credible path back to consistent profitability, despite recent losses and margin pressures. The fresh inclusion in the Russell 2500 and Russell 2500 Value indices may broaden the shareholder base and improve liquidity, but it does not materially change the near term execution risk around IV fluid demand normalization, Novum IQ quality issues, and the removal of stranded costs after past divestitures.

The most directly relevant recent development is Baxter’s governance overhaul, including the 2026 charter and bylaw amendments that reset board size and reflect ongoing shareholder engagement. Together with the interim CFO appointment in March 2026, these changes underscore that leadership stability and capital allocation discipline remain central to the investment case, especially as Baxter works through modest sales growth, recurring net losses, and the operational clean up needed to support any recovery in its core infusion and hospital products.

Yet, while index inclusion may look like a simple win, investors should also be aware of...

Baxter International's narrative projects $12.1 billion revenue and $629.2 million earnings by 2029. This requires 2.2% yearly revenue growth and a $1,610.2 million earnings increase from -$981.0 million today.

Uncover how Baxter International's forecasts yield a $21.54 fair value, a 6% downside to its current price.

Exploring Other Perspectives

While index inclusion hints at broader interest, the most bearish analysts were assuming only about 1.6 percent annual revenue growth and US$623.7 million earnings by 2029, reminding you that opinions can differ sharply and may shift again as this new index status is absorbed.

Explore 6 other fair value estimates on Baxter International - why the stock might be worth as much as 46% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Baxter International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Baxter International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Baxter International's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.